search button
Open Access

Surgical bypass and permanent iodine‑125 seed implantation vs. surgical bypass for the treatment of pancreatic head cancer

  • Authors:
    • Zhenjiang Zheng
    • Yinglong Xu
    • Shu Zhang
    • Guangchun Pu
    • Chi Cui

  • View Affiliations

  • Published online on: June 30, 2017     https://doi.org/10.3892/ol.2017.6495
  • Pages: 2838-2844

  • Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the efficacy and safety of Iodine‑125 (125I) seed implantation in the treatment of locally advanced unresectable pancreatic head cancer. A prospective nonrandomized study was performed using data collected from patients between January 2009 and December 2012. A total of 34 patients underwent surgical bypass and permanent 125I seed implantation (group A), and 32 patients underwent biliary and gastric bypass (group B). The preoperative variables, operative data, postoperative complications and follow‑up information were examined. No significant differences were identified in clinical characteristics, mortality, morbidity and length of hospital stay between the two groups. Tumor responses were significantly different between between patients in group A and B (partial response, 56 vs. 0%, P<0.001; progression, 24 vs. 84%, P=0.013). The time until disease progression was significantly longer in group A compared to group B (8±1 vs. 5±2 months; P<0.001). The median survival time was significantly longer in group A compared to group B (11 vs. 7 months; P<0.001). The quality of life was improved significantly in group A compared to group B. In the first month following surgery, pain scores were improved (24±10 vs. 54±19; P<0.001). Following repeated measure analysis, pain scores were significantly lower in group A compared to group B (P<0.05) at 9 months following surgery. The results of the present study suggest that 125I seed implantation is feasible, safe and effective for the treatment of unresectable pancreatic head cancer.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zheng Z, Xu Y, Zhang S, Pu G and Cui C: Surgical bypass and permanent iodine‑125 seed implantation vs. surgical bypass for the treatment of pancreatic head cancer. Oncol Lett 14: 2838-2844, 2017
APA
Zheng, Z., Xu, Y., Zhang, S., Pu, G., & Cui, C. (2017). Surgical bypass and permanent iodine‑125 seed implantation vs. surgical bypass for the treatment of pancreatic head cancer. Oncology Letters, 14, 2838-2844. https://doi.org/10.3892/ol.2017.6495
MLA
Zheng, Z., Xu, Y., Zhang, S., Pu, G., Cui, C."Surgical bypass and permanent iodine‑125 seed implantation vs. surgical bypass for the treatment of pancreatic head cancer". Oncology Letters 14.3 (2017): 2838-2844.
Chicago
Zheng, Z., Xu, Y., Zhang, S., Pu, G., Cui, C."Surgical bypass and permanent iodine‑125 seed implantation vs. surgical bypass for the treatment of pancreatic head cancer". Oncology Letters 14, no. 3 (2017): 2838-2844. https://doi.org/10.3892/ol.2017.6495